Opdivo and Secondary hypothyroidism - a phase IV clinical study of FDA data

Summary:

Secondary hypothyroidism is reported as a side effect among people who take Opdivo (nivolumab), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Yervoy, and have Malignant melanoma.

The phase IV clinical study analyzes which people have Secondary hypothyroidism when taking Opdivo. It is created by eHealthMe based on reports of 56,294 people who have side effects when taking Opdivo from the FDA, and is updated regularly.

What is Opdivo?

Opdivo has active ingredients of nivolumab. eHealthMe is studying from 56,331 Opdivo users. Check the latest studies of Opdivo.

What is Secondary hypothyroidism?

Secondary hypothyroidism (pituitary gland and its failure to secrete tsh) is found to be associated with 31 drugs and 121 conditions by eHealthMe. Check the latest studies of Secondary hypothyroidism.

On Jul, 13, 2026

56,294 people reported to have side effects when taking Opdivo.
Among them, 20 people (0.04%) have Secondary hypothyroidism.

Could Opdivo cause Secondary hypothyroidism?

Among these 20 people:

How long have people been on Opdivo when they have Secondary hypothyroidism? *

What is the gender of people who have Secondary hypothyroidism when taking Opdivo? *

female: 27.78 %
male: 72.22 %

What is the age of people who have Secondary hypothyroidism when taking Opdivo? *

What are other drugs people take besides Opdivo? *

What are other side effects people have besides Secondary hypothyroidism? *

Secondary Adrenocortical Insufficiency (inadequate secretion of acth by the pituitary gland): 8 people, 40.00%
Adrenal Insufficiency (a condition in which the adrenal glands do not produce adequate amounts of steroids): 7 people, 35.00%
Liver Disorder (liver diseases): 6 people, 30.00%
Headache (pain in head): 5 people, 25.00%
Hypopituitarism (diminished hormone secretion by the pituitary gland, causing dwarfism in children and premature aging in adults): 5 people, 25.00%
Hyponatremia (abnormally low level of sodium in the blood; associated with dehydration): 4 people, 20.00%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 4 people, 20.00%
Malaise (a feeling of general discomfort or uneasiness): 4 people, 20.00%
Fever: 3 people, 15.00%
Hypophysitis (inflammation of the pituitary gland): 3 people, 15.00%

What are the existing conditions these people have? *

Metastatic Renal Cell Carcinoma (spreadable kidney cell tumour): 5 people, 25.00%
Malignant Melanoma (skin cancer rises from melancytes): 5 people, 25.00%
Renal Cell Carcinoma (a kidney cancer): 4 people, 20.00%
Nervous System Disorder (a general class of medical conditions affecting the nervous system): 3 people, 15.00%
Indigestion: 3 people, 15.00%
Gastric Cancer (stomach cancer): 3 people, 15.00%
Diarrhea: 3 people, 15.00%
Cholestasis (a condition where bile cannot flow from the liver to the duodenum): 3 people, 15.00%
Pneumonia: 1 person, 5.00%
Pain: 1 person, 5.00%

* Approximation only. Some reports may have incomplete information.

Do you take Opdivo and have Secondary hypothyroidism?

- Check whether Secondary hypothyroidism is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Opdivo:

Opdivo (56,331 reports)

Browse all side effects of Opdivo:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Secondary hypothyroidism:

Secondary hypothyroidism (31 drugs)

Browse all the conditions that are associated with Secondary hypothyroidism:

Secondary hypothyroidism (121 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on nivolumab (the active ingredients of Opdivo) and Opdivo (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.